JP2022544485A5 - - Google Patents

Info

Publication number
JP2022544485A5
JP2022544485A5 JP2022508487A JP2022508487A JP2022544485A5 JP 2022544485 A5 JP2022544485 A5 JP 2022544485A5 JP 2022508487 A JP2022508487 A JP 2022508487A JP 2022508487 A JP2022508487 A JP 2022508487A JP 2022544485 A5 JP2022544485 A5 JP 2022544485A5
Authority
JP
Japan
Prior art keywords
day
combination therapy
day cycle
days
ipatasertib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508487A
Other languages
English (en)
Japanese (ja)
Other versions
JP7667132B2 (ja
JP2022544485A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045584 external-priority patent/WO2021030248A1/en
Publication of JP2022544485A publication Critical patent/JP2022544485A/ja
Publication of JP2022544485A5 publication Critical patent/JP2022544485A5/ja
Priority to JP2025064712A priority Critical patent/JP2025121905A/ja
Application granted granted Critical
Publication of JP7667132B2 publication Critical patent/JP7667132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508487A 2019-08-12 2020-08-10 Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 Active JP7667132B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064712A JP2025121905A (ja) 2019-08-12 2025-04-10 Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962885732P 2019-08-12 2019-08-12
US62/885,732 2019-08-12
US201962935526P 2019-11-14 2019-11-14
US62/935,526 2019-11-14
PCT/US2020/045584 WO2021030248A1 (en) 2019-08-12 2020-08-10 Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064712A Division JP2025121905A (ja) 2019-08-12 2025-04-10 Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置

Publications (3)

Publication Number Publication Date
JP2022544485A JP2022544485A (ja) 2022-10-19
JP2022544485A5 true JP2022544485A5 (enExample) 2023-08-21
JP7667132B2 JP7667132B2 (ja) 2025-04-22

Family

ID=72193647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022508487A Active JP7667132B2 (ja) 2019-08-12 2020-08-10 Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
JP2025064712A Pending JP2025121905A (ja) 2019-08-12 2025-04-10 Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064712A Pending JP2025121905A (ja) 2019-08-12 2025-04-10 Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置

Country Status (6)

Country Link
US (3) US11576919B2 (enExample)
EP (1) EP4013419A1 (enExample)
JP (2) JP7667132B2 (enExample)
CN (1) CN114206345A (enExample)
TW (1) TW202120096A (enExample)
WO (1) WO2021030248A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3897612A1 (en) 2018-12-19 2021-10-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor
CN114206345A (zh) * 2019-08-12 2022-03-18 豪夫迈·罗氏有限公司 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌
CA3240454A1 (en) * 2021-12-10 2023-06-15 Lacey Morgan LITCHFIELD Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibito
WO2024083716A1 (en) * 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
TW202508598A (zh) * 2023-05-05 2025-03-01 瑞典商阿斯特捷利康公司 癌症療法
CN121586576A (zh) * 2023-06-14 2026-02-27 南京正大天晴制药有限公司 Akt抑制剂在制备预防或治疗乳腺癌药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2694072T4 (fi) * 2011-04-01 2024-09-30 Genentech Inc Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
LT2858989T (lt) * 2012-05-17 2020-08-10 Genentech, Inc. Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
WO2017161253A1 (en) * 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
CN109789141B (zh) 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
TW201904574A (zh) 2017-06-21 2019-02-01 大陸商江蘇恆瑞醫藥股份有限公司 ＳＥＲＤ與ＣＤＫ４／６抑制劑、ＰＩ３Ｋ／ｍＴＯＲ通路抑制劑的用途
CN114206345A (zh) 2019-08-12 2022-03-18 豪夫迈·罗氏有限公司 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌
CA3151330A1 (en) * 2019-09-16 2021-03-25 Christina CURTIS Methods of treatments based upon molecular characterization of breast cancer

Similar Documents

Publication Publication Date Title
JP2022022264A5 (enExample)
JP2019530713A5 (enExample)
JP2017537105A5 (enExample)
JP2013533858A5 (enExample)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2018184465A5 (enExample)
JP2025509510A5 (enExample)
JP2024518947A5 (enExample)
JP2019508476A5 (enExample)
JP2022509262A5 (enExample)
JP2024530189A5 (enExample)
JP2024517085A5 (enExample)
JP2023517535A5 (enExample)
JP2024507367A5 (enExample)
JP2023522415A5 (enExample)
Jhummon et al. Iodine-131 induced hepatotoxicity in previously healthy patients with Grave’s disease
JP6034314B2 (ja) Ｂ細胞リンパ腫の治療における放射線標識化抗ｃｄ２０抗体を使用する組合わせ治療
JP2024506385A5 (enExample)
WO2002078691A1 (en) Duloxetine for treatment of hot flashes
JP2022543679A5 (enExample)
JP2024540044A5 (enExample)
JP2024506347A5 (enExample)
CN1332663C (zh) 用硝酸咪康唑治疗外阴阴道念珠菌病的药盒
JP2006523664A5 (enExample)
JP2025509613A5 (enExample)